Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells: Role in hepatitis B vaccine failure during hepatitis C infection

Vaccine

Volumn 31, Issue 18, 2013, Pages 2238-2245

  Wang, Jia M ^b,c   Ma, Cheng J ^b   Li, Guang Y ^b   Wu, Xiao Y ^b   Thayer, Penny ^a   Greer, Pamela ^a   Smith, Ashley M ^a   High, Kevin P ^d   Moorman, Jonathan P ^a,b   Yao, Zhi Q ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b East Tennessee State University   (United States)

^c MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^d WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Hepatitis B vaccine; Hepatitis C infection; IL 12; IL 17; IL 23; Tim 3

Indexed keywords

HEPATITIS B VACCINE; INTERLEUKIN 12; INTERLEUKIN 23; PROTEIN T CELL IMMUNOGLOBULIN MUCIN DOMAIN 3; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; EX VIVO STUDY; FEMALE; HEPATITIS C; HUMAN; IMMUNOREGULATION; INFECTION; INNATE IMMUNITY; MALE; MONOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH17 CELL; VACCINE FAILURE;

ADAPTIVE IMMUNITY; HEALTHY VOLUNTEERS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS C, CHRONIC; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-23; LIVER; MALE; MEMBRANE PROTEINS; MONOCYTES; SIGNAL TRANSDUCTION; TH17 CELLS;

EID: 84875827526     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.003     Document Type: Article

References (58)

1. Cheruvu S., Marks K., Talal A.H. Understanding the pathogenesis and management of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfection. Clin Liver Dis 2007, 11:917-943.
2. Duberg A.S., Torner A., Davidsdottir L., Aleman S., Blaxhult A., Svensson A., et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat 2008, 15:538-550.
3. Filippini P., Coppola N., Pisapia R., Martini S., Marrocco C., Di Martino F., et al. Virological and clinical aspects of HBV-HCV coinfection in HIV positive patients. J Med Virol 2007, 79:1679-1685.
4. Torbenson M., Kannangai R., Astemborski J., Strathdee S.A., Vlahov D., Thomas D.L. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology (Baltimore, MD) 2004, 39:51-57.
5. Zarski J.P., Bohn B., Bastie A., Pawlotsky J.M., Baud M., Bost-Bezeaux F., et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998, 28:27-33.
6. Keeffe E.B. Acute hepatitis A and B in patients with chronic liver disease: prevention through vaccination. Am J Med 2005, 118(Suppl. 10A):21S-27S.
7. Kramer E.S., Hofmann C., Smith P.G., Shiffman M.L., Sterling R.K. Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis. Dig Dis Sci 2009, 54:2016-2025.
8. Tsai I.J., Chang M.H., Chen H.L., Ni Y.H., Lee P.I., Chiu T.Y., et al. Immunogenicity and reactogenicity of the combined hepatitis A and B vaccine in young adults. Vaccine 2000, 19:437-441.
9. + T cell responses. Vaccine 2011, 29:3169-3176.
10. Malaspina A., Moir S., Orsega S.M., Vasquez J., Miller N.J., Donoghue E.T., et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 2005, 191:1442-1450.
11. Rodriguez-Barradas M.C., Alexandraki I., Nazir T., Foltzer M., Musher D.M., Brown S., et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2003, 37:438-447.
12. Hohler T., Stradmann-Bellinghausen B., Starke R., et al. C4A deficiency and nonresponse to hepatitis B vaccination. J Hepatol 2002, 37:387-392.
13. Verkade M.A., van Druningen C.J., op de Hoek C.T., et al. Decreased antigen-specific T cell proliferation by moDC among hepatitis B vaccine non-responders on haemodialysis. Clin Exp Med 2007, 7:65-71.
14. Albarran B., Goncalves B., Salmen B., et al. Profiles of NK, NKT cell activation and cytokine production following vaccination against hepatitis B. APMIS 2005, 113:526.
15. Bauer T., Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006, 24:572-577.
16. Goncalves L., Albarran B., Salmen S., et al. The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 2004, 326:20-28.
17. Salazar M., Deulofeut H., Granja C., et al. Normal HBsAg presentation and T cell defect in the immune response of nonresponders. Immunogenetics 1995, 41:366-374.
18. Bauer T., Gunther M., Bienzie I., et al. Vaccination against hepatitis B in liver transplant receipients: pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells. Liver Transpl 2007, 13:434-442.
19. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004, 4:336-347.
20. Nishimura H., Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001, 22:265-268.
21. Okazaki T., Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007, 19:813-824.
22. Hafler D.A., Kuchroo V. TIMs: central regulators of immune responses. J Exp Med 2008, 205:2699-2701.
23. Kuchroo V.K., Umetsu D.T., DeKruyff R.H., et al. The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol 2003, 3:454-462.
24. Hikens C.M., Kalinski P., de Boer M., Kapsenberg M.L. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naïve T-helper cells towards the Th1 phenotype. Blood 1997, 90:1920-1926.
25. Feili-Hariri M., Falkner D.H., Morel P.A. Polarization of naïve T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. J Leukoc Biol 2005, 78:656-664.
26. Vasconcellos R., Carter N.A., Rosser E.C., Mauri C. IL-12p35 subunit contributes to autoimmunity by limiting IL-27-driven regulatory responses. J Immunol 2011, 187:3402-3412.
27. Oppmann B., Lesley R., Blom B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
28. Hunter C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005, 5:521-531.
29. Duvallet E., Semerano L., Assier E., et al. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med 2011, 43:503-511.
30. Jin H.T., Anderson A.C., Tan W.G., et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. PNAS 2010, 107:14733-14738.
31. Jones R.B., Ndhlovu L.C., Barbour J.D., et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008, 205:2763-2779.
32. + HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 2010, 1172:2557-4546.
33. Vali B., Jones R.B., Sakhdari A., et al. HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol 2010, 40:2493-2505.
34. Zhang Y., Ma C.J., Wu X.Y., et al. Tim-3 negatively regulates IL-12 production by monocytes during chronic hepatitis C infection. PLoS One 2011, 6:e19664.
35. + monocytes. J Leukoc Biol 2011, 91:189-196.
36. Louten J., Boniface K., Rene de Malefyt W. Development and function of TH17 cells in health and disease. J Allergy Clin Immunol 2009, 123:1004-1011.
37. Khayrullina T., Yen J.H., Jing H., Ganea D. In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. J Immunol 2008, 181:721-735.
38. Lyakh L., Trinchieri G., Provezza L., Carra G., Gerosa F. Regulation of interleukin-12/interleukine-23 production and the T-helper 17 response in human. Immunol Rev 2008, 226:112-131.
39. Stamp L.K., Easson A., Pettersson L., et al. Monocyte derived interleukin (IL)-23 is an important determinant of synovial IL-17A expression in rheumatoid arthritis. J Rheumatol 2009, 36:2403-2408.
40. Oosting M., ter Hofstede H., van de Veerdonk F.L., et al. Role of interleukin-23 (IL-23) receptor signaling for IL-17 responses in human lyme disease. Infect Immun 2011, 79:4681-4687.
41. Gasse P., Riteau N., Vacher R., et al. IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis. PLoS One 2011, 6:e23185.
42. Mok M.Y., Wu H.J., Lo Y., Lau C.S. The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. J Rheumatol 2010, 37:2046-2052.
43. Rocha A.M., Souza C., Rocha G.A., et al. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytope-nia. Haematologica 2011, 96:1560-1564.
44. Zhang J.Y., Zhang Z., Lin F., et al. Interleukin-17-producing CD4 (+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010, 51:81-91.
45. Yao Z.Q., King E., Prayther D., et al. T cell dysfunction by hepatitis C virus core protein involves PD-1/PDL-1 signaling. Viral Immunol 2007, 20:276-287.
46. Yao Z.Q., Prayther D., Trabu C., et al. Differential regulation of SOCS-1 signaling in T and B lymphocytes by HCV core protein. Immunology 2008, 125:197-207.
47. Moorman J.P., Dong Z.P., Ni L., et al. Abnormal B lymphocyte activation associated with TALL-1 overexpression and SOCS-1 deregulation in chronic HCV infection. Immunology 2009, 128:227-235.
48. Yao Z.Q., Ni L., Zhang Y., et al. Differential regulation of T and B lymphocytes by PD-1 and SOCS-1 signaling in hepatitis C virus-associated non-Hodgkin's lymphoma. Immunol Invest 2010, 40:243-264.
49. Ma C.J., Ni L., Zhang Y., et al. PD-1 negatively regulates IL-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages during chronic hepatitis C infection. Immunology 2011, 132:421-431.
50. Frazier A.D., Zhang C.L., Ni L., et al. Program death-1 pathway affects suppressor of cytokine signaling-1 expression in T cells during hepatitis C infection. Viral Immunol 2010, 23:487-495.
51. Zhang Y., Ma C.J., Ni L., et al. Crosstalk between PD-1 and SOCS-1 in HCV core-mediated IL-12 suppression. J Immunol 2011, 186:3093-3103.
52. Ni L., Ma C.J., Zhang Y., et al. PD-1 modulates Regulatory T cells and suppresses T cell responses in HCV-associated Lymphoma. Immunol Cell Biol 2010, 89:535-539.
53. Moorman J.P., Wang J.M., Zhang Y., et al. Tim-3 controls regulatory and effector T cell balance during HCV infection. J Immunol 2012, 189:755-766.
54. + regulatory T cell development through the Tim-3/Gal-9 pathway. Eur J Immunol 2012, [epub ahead of print].
55. Zhou Y., Zhang Y., Yao Z.Q., et al. Dendritic cell-based immunity and vaccination against hepatitis C virus infection. Immunology 2012, 136:385-396.
56. Yao Z.Q., Moorman J.P. Immune exhaustion and immune senescence - two distinct pathways for HBV vaccine failure during HCV and/or HIV infection (review). Arch Immunol Ther Exp 2013, [epub ahead of print].
57. Kortylewski M., Xin H., Kujawski M., et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009, 15:114-123.
58. Wang J.M., Shi L., Ma C.J., et al. Differential regulation of IL-12/IL-23 by Tim-3 drives Th17 cell development during HCV infection. J Virol 2013.